Canadian ADHD Practice Guidelines
(CAP-Guidelines)

Third Edition
Copyright Notice and Permitted Uses of the Guidelines.
No material available at www.caddra.ca (the “Materials”) may be copied, reproduced, republished, uploaded, posted, transmitted, or distributed in any way, except that you may:
(a) Download one copy of the Materials on any single computer for your personal or medical practice use only, provided you keep intact all copyright and other proprietary notices. Where stipulated, specific “tools and patient handouts”, developed for physicians and other medical professionals to use in their practice, may be reproduced by medical professionals or on the advice of medical professionals;
(b) Give a presentation using the Materials, so long as: (i) the purpose of the presentation or distribution is for public education; (ii) you keep intact all copyright and other proprietary notices in the Materials; and (iii) the presentation or distribution is completely non-commercial and you or your organization receive no monetary compensation. If monetary compensation is involved you must provide notice to CADDRA at least ten (10) business days before the presentation and request permission.

Modification of the Materials or use of the Materials for any other purpose, without the prior written consent of CADDRA, is a violation of CADDRA’s copyright and other proprietary rights.

CADDRA Information
Current contact details for the Canadian ADHD Resource Alliance (CADDRA) and information on ordering copies of the Canadian ADHD Practice Guidelines are available on the CADDRA website: www.caddra.ca

Guidelines Citation
The correct citation for this document is: Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines, Third Edition, Toronto ON; CADDRA, 2011.

French Edition
This document is also available in French under the title: Lignes directrices canadiennes pour le TDAH, troisième édition, 2011.

Feedback
Reader suggestions can be provided through a feedback form on our website (www.caddra.ca) or email feedback@caddra.ca

Liability
While great effort has been taken to assure the accuracy of the information, the CAP-Guidelines Committee, CADDRA and its members, designer, printer and others contributing to the preparation of his document cannot accept liability for errors, omissions or any consequences arising from the use of the information. Since this document is not intended to replace other prescribing information, physicians are urged to consult the manufacturers' and other available drug information literature before prescribing.

Please Note:
The CADDRA Canadian ADHD Practice Guidelines (CAP-G) is an active document that will be revised online as new information becomes available. The CADDRA website (www.caddra.ca) will always have the latest version of the Guidelines available free to download and print. This third edition is in binder format to facilitate the replacement of pages with updated versions. Updated documents will be sent out to CADDRA members at periodic intervals. Extra support documents are also accessible to members online.


© 2010 Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA)
TABLE OF CONTENTS

CAP-G Committee Disclosures .................................................................................................. ii
CAP-G Committee & Editorial Consultants ........................................................................... iii
Preface and Acknowledgement ............................................................................................... iv
CADDRA Principles ................................................................................................................. vi
Chapter 1: Diagnosis and Overview of Visits ......................................................................... 1.1
Chapter 2: Differential Diagnosis and Comorbid Disorders .................................................. 2.1
Chapter 3: Specific Issues in Management of ADHD in Children ........................................ 3.1
Chapter 4: Specific Issues in Management of ADHD in Adolescents .................................... 4.1
Chapter 5: Specific Issues in Management of ADHD in Adults ............................................. 5.1
Chapter 6: Psychosocial Interventions and Treatments .......................................................... 6.1
   Supporting Documents
   A: School Letters .................................................................................................................. 6.7
   B: Cognitive Behaviour Therapy .......................................................................................... 6.9
   C: Driving Risk .................................................................................................................... 6.11
Chapter 7: Pharmacological Treatment of ADHD ............................................................... 7.1
   Supporting Documents
   Canadian Medication Chart (in binder front pocket)
   A: Medication Tables per Age Group .................................................................................. 7.9
   B: Specific Information on Medications ............................................................................. 7.15
   C: Side Effects Management .............................................................................................. 7.20
   D: Cardiovascular Risks ..................................................................................................... 7.23
   E: Additional Medication Information ................................................................................. 7.26

<table>
<thead>
<tr>
<th>CHILD/ADOLESCENT TOOLKIT</th>
<th>ADULT TOOLKIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment and Follow-Up Forms</td>
<td>Assessment and Follow-Up Forms</td>
</tr>
<tr>
<td>CADDRA ADHD Assessment Form</td>
<td>8.1</td>
</tr>
<tr>
<td>Weiss Symptom Record (WSR)</td>
<td>8.14</td>
</tr>
<tr>
<td>ADHD Checklist</td>
<td>8.20</td>
</tr>
<tr>
<td>SNAP-IV-26</td>
<td>8.22</td>
</tr>
<tr>
<td>CADDRA Teacher Assessment Form</td>
<td>8.31</td>
</tr>
<tr>
<td>CADDRA Clinician ADHD Baseline/Follow-Up Form</td>
<td>8.34</td>
</tr>
<tr>
<td>CADDRA Patient ADHD Medication Form</td>
<td>8.35</td>
</tr>
<tr>
<td>Handouts</td>
<td></td>
</tr>
<tr>
<td>CADDRA ADHD Information and Resources</td>
<td>8.39</td>
</tr>
<tr>
<td>CADDRA Child Assessment Instructions</td>
<td>8.43</td>
</tr>
<tr>
<td>CADDRA Adolescent Assessment Instructions</td>
<td>8.44</td>
</tr>
<tr>
<td>CADDRA Teachers Instructions</td>
<td>8.45</td>
</tr>
</tbody>
</table>

References ............................................................................................................................ 9.1
DISCLOSURE INFORMATION: CADDRA GUIDELINES COMMITTEE

Canadian ADHD Practice Guidelines (CAP-Guidelines)

Members of the CADDRA Guidelines Committee wish to make the following disclosures:

Dr. Geraldine Farrelly: Eli Lilly Canada Inc. (Speaker, Advisory Board, Research Grants); Janssen-Ortho Inc (Speaker, Advisory Board); Purdue Pharma (Advisory Board); Shire BioChem Inc. (Speaker, Advisory Board).

Dr Martin Gignac: Eli Lilly Canada Inc. (Speaker, Advisory Board); Janssen-Ortho Inc (Speaker, Advisory Board); Purdue Pharma (Advisory Board); Shire BioChem Inc. (Speaker, Advisory Board).

Dr Lily Hechtman: Eli Lilly Canada Inc. (Speaker, Advisory Board, Research Grants); GlaxoSmithKlein (Speaker, Advisory Board, Research Grants); Janssen-Ortho Inc (Speaker, Advisory Board, Research Grants); Purdue Pharma (Speaker, Advisory Board, Research Grants); Shire BioChem Inc. (Speaker, Advisory Board, Research Grants).

Dr. Umesh Jain: Eli Lilly Canada Inc. (Speaker, Advisory Board); Janssen-Ortho Inc (Speaker, Advisory Board); Purdue Pharma (Speaker, Advisory Board, Research Grants); Shire BioChem Inc. (Speaker, Advisory Board); President, TotallyADD.com and Mental Central Inc.

Dr. Laurence Jerome: Janssen-Ortho Inc (Speaker, Advisory Board); Shire BioChem Inc. (Speaker, Advisory Board).

Dr. Diane McIntosh: Eli Lilly Canada Inc. (Speaker, Advisory Board, Research Grants); Janssen-Ortho Inc (Speaker, Advisory Board, Research Grants); Shire BioChem Inc. (Speaker, Advisory Board, Research Grants); Lundbeck, Astra Zeneca, Servier, Sanofi Aventis, Bristol Myers Squibb, Pfizer (Speaker, Advisory Board or Research Grants).

Dr. Simon-Pierre Proulx: Eli Lilly Canada Inc. (Speaker); Janssen-Ortho Inc (Speaker, Advisory Board); Purdue Pharma (Speaker); Shire BioChem Inc. (Speaker).

Dr. Declan Quinn: Eli Lilly Canada Inc. (Speaker, Advisory Board, Research Grants); Janssen-Ortho Inc (Speaker, Advisory Board); Purdue Pharma (Advisory Board); Shire BioChem Inc. (Speaker, Advisory Board).

Dr. Joseph Sadek: Eli Lilly Canada Inc. (Speaker, Research Grants); Janssen-Ortho Inc (Speaker, Research Grants); Purdue Pharma (Speaker, Research Grants); Shire BioChem Inc. (Speaker, Research Grants).

Dr. Derryck Smith: Eli Lilly Canada Inc. (Speaker, Advisory Board); Janssen-Ortho Inc (Speaker, Advisory Board); Purdue Pharma (Speaker, Advisory Board); Shire BioChem Inc. (Speaker, Advisory Board).

Dr. Annick Vincent: Eli Lilly Canada Inc. (Speaker, Advisory Board); Janssen-Ortho Inc (Speaker, Advisory Board); Purdue Pharma (Speaker, Advisory Board); Shire BioChem Inc. (Speaker, Advisory Board, Research Grants); Biovail (Speaker).

Dr. Margaret Weiss: Eli Lilly Canada Inc. (Speaker, Advisory Board, Research Grants); Janssen-Ortho Inc (Speaker, Advisory Board, Research Grants); Purdue Pharma (Speaker, Advisory Board, Research Grants); Shire BioChem Inc. (Speaker, Advisory Board, Research Grants).
EDITORIAL BOARD – CADDRA GUIDELINES COMMITTEE

Canadian ADHD Practice Guidelines (CAP-Guidelines)
The Canadian ADHD Practice Guidelines is dedicated to children, adolescents and adults with ADHD and their families

3rd Edition Editors Dr. Margaret Weiss and Dr. Annick Vincent
Supervising Editor Dr. Umesh Jain
Editorial Consultants Heidi Bernhardt, Executive Director, CADDRA
Niamh McGarry, Web and Project Manager, CADDRA

Editorial Board – CAP-G Committee
Lily Hechtman MD, FRCPC, Professor, Psychiatry & Paediatrics, McGill University, Montreal, QC
Geraldine Farrelly MD, FRCPC, DCH, DObst, Clinical Associate Professor, Paediatrics & Psychiatry, University of Calgary, Calgary, AB
Martin Gignac MD, FRCPC, Clinical Assistant Professor, Université de Montréal, Montreal, QC
Umesh Jain MD, FRCPC, DABPN, PhD, MEd, Associate Professor, Psychiatry, University of Toronto, Toronto, ON
Laurence Jerome MB. ChB, MSc, FRCPsych, FRCPC, Adjunct Professor, Psychiatry, The University of Western Ontario, London, ON
Diane McIntosh MD, FRCPC, Clinical Assistant Professor, Psychiatry, University of British Columbia, Vancouver, BC
Simon-Pierre Proulx MD, Groupe de médecins de famille, Loretteville, Québec, QC
Declan Quinn MD, FRCPC, Professor, Psychiatry, University of Saskatchewan, Saskatoon, SK
Joseph Sadek MD, FRCPC, DABPN, MBA, Assistant Professor, Psychiatry, Dalhousie University, Halifax, NS
Derryck Smith MD, FRCPC, Clinical Professor, Psychiatry, University of British Columbia, Vancouver, BC
Annick Vincent MD, FRCPC, Centre Médical l’Hêtrière, Clinique FOCUS, Saint-Augustin-de-Desmaures
Clinical Professor, Psychiatry, Laval University, Quebec, QC
Margaret Weiss PhD, MD, FRCPC, Clinical Professor, Psychiatry, University of British Columbia, Vancouver, BC

External Reviewers
Thomas E. Brown Ph.D., Associate Director, Yale Clinic for Attention and Related Disorders, Yale University School of Medicine, New Haven, CT
Peter S. Jensen MD, President & CEO, The Reach Institute, NY, Professor of Psychiatry, Mayo Clinic, Rochester, MN
Sarah Shea MD, FRCPC, Associate Professor, Paediatrics, Dalhousie University, Halifax, NS
John Yaremko MD, FRCPC, Assistant Professor, Paediatrics, McGill University, Montreal, Quebec

Additional Contributors
Rosemary Tannock, PhD, Professor of Psychiatry, University of Toronto, Toronto, ON
Rosalia Yoon, PhD candidate, Centre for Addiction and Mental Health, Toronto, Ontario (contributor of ADHD and sleep section, Chapter 2)
Michael Zwiers Ph.D. Psychologist & Manager, Clinical Services and Krista Forand, Intake Clinician, Calgary Learning Centre, Calgary, AB (contributors to Chapter 6)

Special thanks to all the clinicians who helped develop the new Guidelines, particularly the family practitioners and paediatricians who provided feedback on the new CADDRA ADHD Assessment Toolkit.
PREFACE AND ACKNOWLEDGEMENT

Who is CADDRA? The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) is a national, independent, not-for-profit association whose members are drawn from family practice, paediatrics, psychiatry (child, adolescent and adult), psychology and other health professions. We hope to support individuals with Attention Deficit Hyperactivity Disorder (ADHD) and their families and provide ongoing support to those who are delivering care for ADHD in their communities across Canada.

The evolution of the 3rd Edition. This third edition of the CADDRA Canadian ADHD Practice Guidelines (CAP-G or Guidelines) evolved from earlier editions of the CAP-G published in 2006¹ and 2008². The Guidelines were developed to help Canadian physicians diagnose and treat ADHD across the lifespan. Many ADHD specialists and general physicians contributed to its writing. The Editorial Committee is made up of the CADDRA Executive Board. All contributing authors are experts selected on the basis of their contributions to treatment, education and research in the area of ADHD and represent several different disciplines from across Canada.

These Guidelines are unique (even from other Guidelines or Toolkits in the world) in that they:

1. have been produced by a multidisciplinary team
2. have been translated into French and English (including additional online material)
3. are specific to Canadian practice
4. include the entire lifespan of this disorder
5. speak to diagnosis and treatment in real-life conditions of practice where resources are limited
6. use paper and fonts that make for high resolution photocopies and are formatted so that they can be easily downloaded from the CADDRA website
7. recognize that ADHD is a disorder which will require treatment using a shared care model between specialists and primary care practitioners
8. stipulate both what can be handled in primary care and recommend when referral to specialists may be required
9. express our belief that the best care comes from optimizing care for each individual. We do not prioritize medications on a hierarchy or algorithm that can be considered appropriate for all patients
10. inform physicians but also empower patients to make informed choices in a collaborative process of care.

Features of the 3rd Edition

1. The current CAP-G is an active document that will be revised online as new information is obtained, and reprinted as required.
2. The binder format will allow the clinician to add and remove sections as revisions are made and for purposes of photocopying. The binder can also be used to file additional CADDRA information and newsletters.
3. The final drafts were sent for independent review by clinicians across the country and in the US.
4. The authors were not paid in any way for their contribution to the CAP-G. Declarations of conflicts of interests for each author are found on page ii.
5. The Guidelines receives no financial grants from industry. The cost of production is recouped entirely from sales.
f) The rating scales and tools developed by CADDRA are free and were created with the express purpose of being user-friendly in order to allow assessment of ADHD in primary care to become both a rigorous and efficient process. Written permission for use of the additional scales has been obtained.

g) There is a new section on psychosocial treatments.

h) The medication sections have been updated and regrouped.

i) The Guidelines are part of a comprehensive educational program to help clinicians reach the highest standards of clinical care.

j) These Guidelines are available free of charge on the CADDRA website, www.caddra.ca.

The Guidelines should be used by clinicians for interactive instruction on the diagnosis and treatment of ADHD across the lifespan. The website allows clinicians and their patients to download information, diagnostic instruments, forms and scales – all of which have been selected based on their validity, reliability and accessibility. References and an index of terms are included at the end of the document.

Evidenced-based versus Consensus-based. The CAP-Guidelines Committee has reviewed the other ADHD guidelines and consensus statements in current use. There are many, including the American Academy of Child and Adolescent Psychiatry Guidelines, the American Academy of Pediatrics Guidelines, the Texas Children’s Medication Algorithm Project, the American Psychiatric Association Diagnostic and Statistical Manual – Fourth Edition- Text Revision, the European Treatment Guidelines, the National Institute of Health and Clinical Excellence (NICE) Guidelines and the British Association for Psychopharmacology Guidelines. While there is a high degree of consensus among these publications, there are also very significant international differences. The most obvious difference is seen in the recent NICE Guidelines, which recommend medication treatment only in more severe cases, whereas the American practice is almost the opposite: start with medication and then see what else is necessary. In addition, the use of different diagnostic instruments, such as ICD-10 or DSM-IV, has also led to differences in what population is being referenced in a particular Guideline. The Canadian practice is holistic-based care, individualized to the patient, with medications as part of the treatment agenda.

The editors have been careful to identify which facts are consensus-based. This information is noted in the text. Evidence-based (EB) data is cited in the literature detailed in the reference section. CB data was produced, as it suggests, by a consensus of the experts within the CADDRA Board after careful and rigorous consideration of the current facts. CB decisions have been made if there was no current EB data available to deal with a specific clinical issue or where the EB data may have been impractical in the Canadian environment.

It is clear that service delivery for ADHD is only feasible if it is within the scope of primary care practice. There is no country in the world with a sufficient number of specialists to provide diagnosis and treatment for what is one of the most common disorders of childhood and affects 4.4% of adults. There are few if any guidelines available to assist physicians treating adults with a childhood history of ADHD. By providing these Guidelines, in English and in French, it is our hope that this impaired and treatable population will be appropriately serviced in the public healthcare system.
CADDRA GUIDING PRINCIPLES

Vision
To improve the quality of life for patients and their families living with Attention Deficit Hyperactivity Disorder (ADHD) while maximizing their potential across the lifespan.

Mandate
CADDRA is a national Canadian alliance of professionals working in the area of ADHD and dedicated to world class education, training and advocacy.

Mission (Objectives)
- To take a leadership role in disseminating information on ADHD in Canada
- To develop and update the Canadian ADHD Practice Guidelines (CAP-Guidelines)
- To facilitate development and implementation of training standards in the care of ADHD patients
- To share information among all stakeholder groups. To advocate to governments, teaching environments, employment organizations or others who interface with ADHD patients.

CADDRA GUIDELINES – CORE PRINCIPLES

Principles for Assessment and Diagnosis
1. The clinician must be accredited by his or her regional and national associations
2. The clinician has to be adequately trained in order to understand the developmental context of ADHD
3. The diagnosis needs to reflect an understanding of multi-systemic issues that relate to ADHD (e.g. the educational/vocational, psychosocial, psychiatric and the medical interfaces)
4. Every patient deserves to be seen in a place of safety that promotes the therapeutic alliance with the clinician
5. There should be no cost for distributing or scoring any of the materials from the CAP-G so that there is universal access to the best assessment materials
6. Symptoms and functional impairment must be recorded using valid, reliable and sensitive rating scales to evaluate symptom frequency, severity, and outcome
7. The clinician must document all relevant findings in a timely manner both for purposes of outcome but also for review
8. The results of the assessment should be communicated to the patient and their family with clarity and compassion.

Principles for Intervention
The five tiers of holistic-based care
ADHD is a chronic medical condition and requires long-term planning. It must include regular contact with the patient and the family about progress and performance. The family doctor, along with the pediatrician and child psychiatrist (in the case of children and adolescents) or the psychiatrist (when dealing with adults), are key professionals. Treatment should be multi-modal; there is no one treatment for ADHD (including medication) that has been demonstrated to assure a good long-term outcome in isolation. 

1. Adequate education of patients and their families

Psychoeducation must be the first intervention. The more educated the family and the patient are, the better are their choices and the response to treatment. An integrated approach to ADHD education includes information on interventions related to:

a) support for families and their advocacy of ADHD
b) psychosocial and medical treatments
c) patient, parent and school management, and
d) occupational/educational accommodations.

2. Behavioural and/or occupational interventions

The core strategy is to develop better habits that, ultimately, may lead to coping strategies that minimize the patient’s impairments. ADHD patients may take longer to integrate such habits into their lives. The therapeutic alliance between patient and clinician is necessary and an optimistic attitude can facilitate this process.

3. Psychological treatment

ADHD patients are at significant risk of being targets of intentional and unintentional conflict. There is a direct effect on their self-esteem and on the well-being of their families. They require a positive environment, sensitivity and understanding. Interventions may include individual and/or family support, counselling and therapy to help minimize damage to self esteem from such experiences. Cognitive behavioural psychotherapy has been demonstrated to be a useful adjunctive treatment for adolescents and adults, though evidence in children is still controversial.

4. Educational accommodations

ADHD should be classified as a developmental neuropsychiatric disorder and the patient should have access to educational accommodations where necessary. ADHD should be protected by the same type of legislation available in the United States, where every child is entitled to the education that meets his or her needs. By contrast, ADHD alone does not qualify a student for an “exceptional” educational designation in some Canadian provinces. This must change.

5. Medical management (as a way to facilitate the other interventions)

ADHD is a medical condition that requires an understanding of the medical options. Every patient should have access to the best medications available, regardless of their financial situation. Each patient must be treated uniquely. There is no one medication that is suitable for every ADHD patient. The guiding principle of medication management is to start low and go slow for most patients, though weight-based guidelines may be used as a way of estimating dose during the initial prescription.

Principles of Informed Consent

Ensure that the patient and family have had an adequate opportunity to educate themselves and then ask relevant questions regarding the disorder and its treatment. The following ‘Principles of Informed Consent’ should be reviewed.

Patients and their families need to be educated as follows:

1. They need to understand the proposed treatment plan
2. There must be a discussion of the risks and benefits of the prescribed treatment
3. Information on alternatives to treatment must be provided
4. There needs to be discussion regarding potential risks of no treatment.
A collaborative and long-term relationship between physician and patient is critical. Many doctors and patients associate the basis of their relationship with the prescription. When the medication is discontinued, so is the doctor. Instead, the hope would be that the basis of the relationship is long-term treatment of the disorder that respects the concerns of the child, adult or family in order to maintain the therapeutic alliance.

**Principles of Advocacy**

Patients and their families must be empowered. Facilitate this process by participating in advocacy campaigns that advance patient care. These will be posted on the [www.caddra.ca](http://www.caddra.ca) and [www.caddac.ca](http://www.caddac.ca) websites.

**ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD</td>
<td>Attention Deficit Hyperactivity Disorder</td>
</tr>
<tr>
<td>ADHD-C</td>
<td>ADHD, Predominantly Combined Subtype</td>
</tr>
<tr>
<td>ADHD-HI</td>
<td>ADHD, Predominantly Hyperactive-Impulsive Subtype</td>
</tr>
<tr>
<td>ADHD-I</td>
<td>ADHD, Predominantly Inattentive Subtype</td>
</tr>
<tr>
<td>AMP</td>
<td>Amphetamines</td>
</tr>
<tr>
<td>ASD</td>
<td>Autism Spectrum Disorder</td>
</tr>
<tr>
<td>ASPD</td>
<td>Antisocial Personality Disorder</td>
</tr>
<tr>
<td>ASRS</td>
<td>Adult Self Report Scale</td>
</tr>
<tr>
<td>ATX</td>
<td>Atomoxetine Hydrochloride</td>
</tr>
<tr>
<td>BAD</td>
<td>Bipolar Affective Disorder</td>
</tr>
<tr>
<td>BD</td>
<td>Bipolar Disorder</td>
</tr>
<tr>
<td>BPD</td>
<td>Borderline Personality Disorder</td>
</tr>
<tr>
<td>CAAT</td>
<td>CADDRA ADHD Assessment Toolkit</td>
</tr>
<tr>
<td>CADDRA</td>
<td>Canadian Attention Deficit Hyperactivity Disorder Resource Alliance</td>
</tr>
<tr>
<td>CADDAC</td>
<td>Centre for ADHD/ADD Advocacy, Canada</td>
</tr>
<tr>
<td>CAP-G</td>
<td>Canadian ADHD Practice Guidelines</td>
</tr>
<tr>
<td>CB</td>
<td>Consensus Based</td>
</tr>
<tr>
<td>CBT</td>
<td>Cognitive Behaviour Therapy</td>
</tr>
<tr>
<td>CD</td>
<td>Conduct Disorder</td>
</tr>
<tr>
<td>CV</td>
<td>Cardiovascular</td>
</tr>
<tr>
<td>DCD</td>
<td>Developmental Coordination Disorder</td>
</tr>
<tr>
<td>DEX</td>
<td>Dextro-amphetamine</td>
</tr>
<tr>
<td>DSM-IV-TR</td>
<td>Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, text revision</td>
</tr>
<tr>
<td>EDS</td>
<td>Excessive Daytime Sleeping</td>
</tr>
<tr>
<td>EB</td>
<td>Evidence Based</td>
</tr>
<tr>
<td>GAD</td>
<td>Generalized Anxiety Disorder</td>
</tr>
<tr>
<td>HAM-A</td>
<td>The Hamilton Anxiety Rating Scale</td>
</tr>
<tr>
<td>HAM-D</td>
<td>The Hamilton Rating Scale for Depression</td>
</tr>
<tr>
<td>IH</td>
<td>Idiopathic Hypersomnia</td>
</tr>
<tr>
<td>IPT</td>
<td>Interpersonal Psychotherapy</td>
</tr>
<tr>
<td>JDQ</td>
<td>Jerome Driving Questionnaire</td>
</tr>
<tr>
<td>LD</td>
<td>Learning Disability</td>
</tr>
<tr>
<td>MD</td>
<td>Major Depression</td>
</tr>
<tr>
<td>MPH</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Clinical Excellence</td>
</tr>
<tr>
<td>OCD</td>
<td>Obsessive Compulsive Disorder</td>
</tr>
<tr>
<td>ODD</td>
<td>Oppositional Defiant Disorder</td>
</tr>
<tr>
<td>PD</td>
<td>Personality Disorder</td>
</tr>
<tr>
<td>PDD</td>
<td>Pervasive Developmental Disorder</td>
</tr>
<tr>
<td>PLMS</td>
<td>Periodic Limb Movements in Sleep</td>
</tr>
<tr>
<td>RLS</td>
<td>Restless Legs Syndrome</td>
</tr>
<tr>
<td>S-ADHD</td>
<td>Secondary Attention Deficit Hyperactivity Disorder</td>
</tr>
<tr>
<td>SDB</td>
<td>Sleep Disordered Breathing</td>
</tr>
<tr>
<td>SUD</td>
<td>Substance Use Disorder</td>
</tr>
<tr>
<td>TS</td>
<td>Tourette's Syndrome</td>
</tr>
<tr>
<td>WISC</td>
<td>Wechsler Intelligence Scale for Children</td>
</tr>
<tr>
<td>WFIRS-P</td>
<td>Weiss Functional Impairment Scale – Parent Report</td>
</tr>
<tr>
<td>WFIRS-S</td>
<td>Weiss Functional Impairment Scale – Self Report</td>
</tr>
<tr>
<td>WSR</td>
<td>Weiss Symptom Record</td>
</tr>
<tr>
<td>Y-BOCS</td>
<td>Yale-Brown Obsessive Compulsive Scale</td>
</tr>
</tbody>
</table>